© 2020 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Multiple Myeloma
Matous Evaluates Treatment Strategies for Transplant-Ineligible Multiple Myeloma
May 26, 2020
Jeffrey Matous, MD, discussed strategies for treating a 51-year-old male patients with transplant-ineligible multiple myeloma, during a live Targeted Oncology case-based peer perspectives conversation with other experts.
FDA Approval Sought for Selinexor in Previously Treated Multiple Myeloma
May 20, 2020
"If approved, we believe selinexor could become an important addition to the treatment paradigm for patients with relapsed or refractory multiple myeloma, and we look forward to working with the FDA during the review process."
Isatuximab With Carfilzomib and Dexamethasone Extends PFS in Relapsed Multiple Myeloma
May 12, 2020
"This is the second positive phase 3 trial for Sarclisa, further supporting the potential our medicine has to improve outcomes for patients struggling with relapsed multiple myeloma.”
Expert Addresses Rationale for Evaluating NKTR-255 in Multiple Myeloma
May 07, 2020
In an interview with Targeted Oncology, Nikhil C. Munshi, MD, discussed the rationale for evaluating NKTR-255 as treatment of patients with multiple myeloma.
Updated MAIA Trial Data Show Improved Survival for Multiple Myeloma
May 04, 2020
Nizar Bahlis, MD, discusses the findings from the randomized phase III MAIA trial, which evaluated the combination regimen of daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in transplant-ineligible patients with multiple myeloma.
FDA Approves Subcutaneous Daratumumab With Hyaluronidase in Multiple Myeloma Indications
May 01, 2020
The FDA has approved the use of daratumumab in combination with hyaluronidase-fihj (Darzalex Faspro) for the treatment of adult patients with newly diagnosed or relapsed/refractory multiple myeloma. The newly approved product allowed for subcutaneous dosing of daratumumab.
Close to 90% of Patients With Myeloma Achieve Response with RVD Induction
April 28, 2020
High response rates were observed in patients with newly diagnosed multiple myeloma with induction treatment of bortezomib and lenalidomide plus dexamethasone after autologous stem cell transplant.
Analyzing the Outcomes With Different Treatment Techniques in Myeloma
April 17, 2020
Shaji K. Kumar, MD, discusses how patients with multiple myeloma respond to different types of therapy.
Physicians Successfully Treat Severe COVID-19 in Patient With Multiple Myeloma
April 11, 2020
In the epicenter of the coronavirus disease 2019—Wuhan, China—a 60-year-old patient with multiple myeloma presented with chest tightness with no fever or cough, in early February. The patient was successfully treated with the anti–interleukin-6 receptor antibody tocilizumab, according to a case study published in Blood Advances.
FDA Approval Sought for Ide-cel in Relapsed/Refractory Multiple Myeloma
March 31, 2020
A Biologics License Application has been submitted to the FDA for the investigational B-cell maturation antigen-directed chimeric antigen receptor T cell immunotherapy idecabtagene vicleucel as treatment of patients with multiple myeloma who have received at least 3 prior therapies.